Results of a Phase 1 study, rcently presented at the 2011 Annual Meeting of the American Society of Hematology, showed three of five patients in their second or third remissions had longer complete responses with CNDO-109 than with other therapies, says Dr. Markey.
FORBES: Intrepid Investors Eye Use Of Pig Whipworm Eggs To Quell Crohn's Disease and MS